{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:48Z","timestamp":1753891848179,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The primary treatment strategies for melanoma include surgical excision, chemotherapy, and radiotherapy. However, the efficacy of these treatments is often limited by drug resistance, recurrence, and severe side effects. Therefore, we aimed to develop a targeted drug delivery system capable of selectively locating tumor sites to minimize systemic toxicity and enhance therapeutic efficacy. This cell drug delivery system can also deliver chemotherapeutic drugs to the tumor microenvironment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We treated B16F10 cells with hyperosmotic cold shock (HCS) to obtain and characterize HCS cells. We then investigated the anti-tumor effects and immune activation capabilities of these cells and explored their potential as a targeted drug delivery system.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>HCS cells not only maintained an intact cellular structure and tumor antigens but also exhibited high expression of the homologous melanoma-associated antigen glycoprotein 100. These cells demonstrated an exceptional capacity for loading and releasing doxorubicin, which has chemotherapeutic anti-tumor effects. HCS cells can precisely target the tumor microenvironment to minimize systemic toxicity, inducing an immune response by activating CD3+ and CD4+ T cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>HCS cells are non-carcinogenic, with both cellular and tumor antigens intact; thus, they are suitable drug delivery carriers. Our findings highlight the potential of HCS cells for carrying doxorubicin because of their high drug-loading efficiency, effective tumor-targeting and anti-tumor effects. Therefore, our results will facilitate the development of melanoma treatments that have higher efficacy than those in the literature.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1403719","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T04:28:47Z","timestamp":1714537727000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Hyperosmotic cold shock mouse melanoma cells encapsulated with doxorubicin for targeted treatment of melanoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Weihui","family":"Kong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhui","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congxiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,5,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 world health organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2020.305567","article-title":"New systematic therapies and trends in cutaneous melanoma deaths among US whites, 1986\u20132016","volume":"110","author":"Berk-Krauss","year":"2020","journal-title":"Am J Public Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.15537\/smj.2016.4.15017","article-title":"Primary Malignant melanoma","volume":"37","author":"M\u0131s\u0131r","year":"2016","journal-title":"SMJ"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of deCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","volume":"37","author":"Leiter","year":"2019","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.0c09969","article-title":"Stellate plasmonic exosomes for penetrative targeting tumor NIR-II thermo-radiotherapy","volume":"12","author":"Zhu","year":"2020","journal-title":"ACS Appl Mater Interfaces"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004769","article-title":"Bright bacterium for hypoxia-tolerant photodynamic therapy against orthotopic colon tumors by an interventional method","volume":"8","author":"Zhu","year":"2021","journal-title":"Advanced Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S338488","article-title":"B16 membrane-coated vesicles for combined photodynamic therapy and immunotherapy shift immune microenvironment of melanoma","volume":"17","author":"Wang","year":"2022","journal-title":"IJN"},{"key":"B10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/adhm.201900612","article-title":"Cell membrane-coated magnetic nanocubes with a homotypic targeting ability increase intracellular temperature due to ROS scavenging and act as a versatile theranostic system for glioblastoma multiforme","volume":"8","author":"Tapeinos","year":"2019","journal-title":"Adv Healthcare Materials"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S306269","article-title":"Dual modal imaging-guided drug delivery system for combined chemo-photothermal melanoma therapy","volume":"16","author":"Zhang","year":"2021","journal-title":"IJN"},{"key":"B12","unstructured":"YauTO\n          Shakespeare Street, NottinghamNottingham Trent UniversityAlternations of microRNAs, the microbiome, and gut-host interactions in gastrointestinal diseases2022"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122034","article-title":"A type I AIE photosensitiser-loaded biomimetic nanosystem allowing precise depletion of cancer stem cells and prevention of cancer recurrence after radiotherapy","volume":"295","author":"Ning","year":"2023","journal-title":"Biomaterials"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2023.146276","article-title":"Platelet membrane fusion liposome loaded with type I AIE photosensitizer to induce chemoresistance cancer pyroptosis and immunogenic cell death for enhancing cancer immunotherapy","volume":"476","author":"Chen","year":"2023","journal-title":"Chem Eng J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102290","article-title":"Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study","volume":"65","author":"Bai","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/jamaoncol.2020.0726","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.3c06025","article-title":"\u201cZombie\u201d Macrophages for targeted drug delivery to treat acute pneumonia","volume":"15","author":"Xu","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging cellular therapies for cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.7b00526","article-title":"Leveraging engineering of cells for drug delivery","volume":"51","author":"Chen","year":"2018","journal-title":"Acc Chem Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/SMMD.20220034","article-title":"Freezing biological organisms for biomedical applications","volume":"1","author":"Kuang","year":"2022","journal-title":"Smart Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc3013","article-title":"Cryo-shocked cancer cells for targeted drug delivery and vaccination","volume":"6","author":"Ci","year":"2020","journal-title":"Sci Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1841392","article-title":"Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse","volume":"9","author":"Guo","year":"2020","journal-title":"OncoImmunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1021\/acsami.2c16806","article-title":"Cryo-shocked cancer cells as an oncolytic adenovirus reservoir for glioblastoma immunotherapy","volume":"15","author":"Liu","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/mrd.22489","article-title":"The ImageJ ecosystem: An open platform for biomedical image analysis","volume":"82","author":"Schindelin","year":"2015","journal-title":"Mol Reprod Dev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174727","article-title":"Hepatocyte nuclear factor 4 gamma (HNF4G) is correlated with poor prognosis and promotes tumor cell growth by inhibiting caspase-dependent intrinsic apoptosis in colorectal cancer","volume":"916","author":"Chen","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121635","article-title":"Phytochemical natural killer cells reprogram tumor microenvironment for potent immunotherapy of solid tumors","volume":"287","author":"Lei","year":"2022","journal-title":"Biomaterials"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-022-00003-7","article-title":"Comparing development strategies for PD1\/PDL1-based immunotherapies","volume":"21","author":"Li","year":"2022","journal-title":"Nat Rev Drug Discovery"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/advs.201903332","article-title":"Supramolecular prodrug nanovectors for active tumor targeting and combination immunotherapy of colorectal cancer","volume":"7","author":"Hu","year":"2020","journal-title":"Advanced Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2010.02.004","article-title":"Whole tumor antigen vaccines","volume":"22","author":"Chiang","year":"2010","journal-title":"Semin Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aan5692","article-title":"A melanin-mediated cancer immunotherapy patch","volume":"2","author":"Ye","year":"2017","journal-title":"Sci Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1012863","article-title":"gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma","volume":"364","author":"Schwartzentruber","year":"2011","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2726-1","article-title":"Melanoma treatment: from conventional to nanotechnology","volume":"144","author":"Mishra","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041269","article-title":"Biomimetic boron nitride nanoparticles for targeted drug delivery and enhanced antitumor activity","volume":"15","author":"Li","year":"2023","journal-title":"Pharmaceutics"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/biom11081213","article-title":"Cell adhesion molecules in normal skin and melanoma","volume":"11","author":"D\u2019Arcy","year":"2021","journal-title":"Biomolecules"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2217\/nnm-2019-0388","article-title":"Cell membrane-coated nanoparticles: research advances","volume":"15","author":"Zou","year":"2020","journal-title":"Nanomedicine"},{"key":"B39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2147\/IJN.S266676","article-title":"Externally triggered novel rapid-release sonosensitive folate-modified liposomes for gemcitabine: development and characteristics","volume":"16","author":"Omar","year":"2021","journal-title":"IJN"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147589","article-title":"Doxorubicin-induced fetal mesangial cell death occurs independently of TRPC6 channel upregulation but involves mitochondrial generation of reactive oxygen species","volume":"22","author":"Matthews","year":"2021","journal-title":"IJMS"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1403719\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T04:28:53Z","timestamp":1714537733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1403719\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":40,"alternative-id":["10.3389\/fonc.2024.1403719"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1403719","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2024,5,1]]},"article-number":"1403719"}}